Abstract:Abstract Introduction: Breast cancer is the primary type of female cancer in the UK. We have recently shown that reduced expression of BMPR-IB correlates with poor prognosis, and may be useful as a prognostic indicator in breast cancer (1). This current study aimed to see if a role for the BMP type II receptor (BMPR-II), also exists in the progression of breast cancer.Methods: Expression of BMPR-II was examined in a cohort of 32 normal breast tissue and 112 primary breast tumour tissue samples. Transcript levels of BMPR-II were then determined using quantitative real time-PCR and protein levels were assessed using immunohistochemical (IHC) staining. Finally, ribozyme transgenes were constructed to knock-down BMPR-II expression in MDA-MB-231 cells. The effect this had in vitro cell growth was examined.Results: In normal breast tissue, IHC staining demonstrated strong expression of BMPR-II, specifically in the epithelial cells. In comparison to the normal breast tissue, reduced expression of BMPR-II was evident in the breast tumour samples. BMPR-II transcript levels were further determined using Q-PCR. A trend was evident in that patients with poor prognosis (0.012±0.09) including those with metastasis, local recurrence and breast cancer deaths, demonstrated reduced BMPR-II expression compared to disease free patients (33±13, p=0.09 vs. poor prognosis). Furthermore, lower expression levels were seen in patient samples with a Nottingham Prognosis Index (NPI) greater than 5.4 (poor prognosis group) (18±17) compared to those with NPI <3.4 (good prognosis group) (41±18, p=0.19). Finally, BMPR-II expression was markedly lower in advanced breast cancer of TNM stage 3 and 4 (0±0.1) compared with those of early stage of the disease (TNM1, 46±17, both p<0.01). Despite the clear trend seen, the majority of the data was not found to be significant, suggesting that unlike BMPR-IB, BMPR-II is less useful in predicting prognosis of breast cancer. However, knocking down BMPR-II expression in MDA-MB-231 breast cancer cell line resulted in a reduction of in vitro cell growth, suggesting BMPR-II may play a positive role in breast cancer cell growth. The absorbance of MDA-MB-231BMPR-IIKO cells at day 5 was 1.29±0.09, p<0.01 compared with MDA-MB-231WT (1.90±0.18) and MDA-MB-231GFP control cells (2.30±0.23).Conclusion: This study reveals a trend for BMPR-II in that its expression appears to be reduced in breast cancer patients with poor prognosis. Despite this, it is not as useful of a prognostic indicator as its type I counterpart BMPR-IB, suggesting that in breast cancer progression, BMPR-IB plays a more important role. However, reduced expression of BMPR-II in MDA-MB-231 resulted in a promotion of cell growth, suggesting that BMPs in breast cancer cells may act via BMPR-II to promote tumour growth. However, this needs further investigation.Reference:1. Bokobza SM, et al. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genom Proteom, 2009, 6, 101-108 Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3039.

Bone Morphogenetic Protein 10 (Bmp-10) Inhibits Growth of Breast Cancer Cells and Correlates with Poor Prognosis

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

Bone Morphogenetic Protein 9 Regulates the Cross-Talk Between Breast Cancer Cells and Bone Marrow Mesenchymal Stem Cells

Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway.

Bone Morphogenetic Protein 9 Overexpression Reduces Osteosarcoma Cell Migration and Invasion

Effects of human bone morphogenetic protein 9 on migration and apoptosis of human breast cancer cells in simulated bone microenvironment in vitro

Reduced Expression of BMPR-IB Correlates with Poor Prognosis and Increased Proliferation of Breast Cancer Cells.

Effects of BMP9 over-expression on proliferation and migration of human breast cancer MDA-MB-231 cells in simulated breast adipose microenvironment in vitro and its possible mechanism

BMPR-II Mediates Positive Regulation on in Vitro Cell Growth, the Potential Implications for Breast Cancer.

The aberrant expression of bone morphogenetic protein 12 (BMP-12) in human breast cancer and its potential prognostic value

Expression of Bone Morphogenetic Protein-10 (BMP10) in Human Urothelial Cancer of the Bladder and Its Effects on the Aggressiveness of Bladder Cancer Cells in Vitro.

Bone morphogenetic protein 1: a prognostic indicator and potential biomarker in three cancer types

Effect of Bone Morphogenetic Protein-2 on Proliferation and Apoptosis of Gastric Cancer Cells

BMP-6 Inhibits Cell Proliferation by Targeting Microrna-192 in Breast Cancer

Deregulated Bone Morphogenetic Proteins and Their Receptors Are Associated with Disease Progression of Gastric Cancer.

BMP-6 Inhibits MMP-9 Expression by Regulating Heme Oxygenase-1 in MCF-7 Breast Cancer Cells

Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4

Upregulated bone morphogenetic protein 8A (BMP8A) in triple negative breast cancer (TNBC) and its involvement in the bone metastasis

Noggin, Impact on in Vitro Cell Growth, Expression Pattern and the Prognostic Value in Breast Cancer.